How digital platforms and policy shifts reshape GLP-1 affordability

by JMIR Publications

edited by Sadie Harley, reviewed by Andrew Zinin

Sadie Harley

Scientific Editor

Meet our editorial team
Behind our editorial process

Andrew Zinin

Lead Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

proofread

The GIST Add as preferred source

A News and Perspectives report on emerging pharmaceutical access models in the United States has been published in the Journal of Medical Internet Research. In "Affordable GLP-1? When Digital Platforms Meet Policy Reform", a JMIR Correspondent Xiangming Jenny Zhan investigates how a convergence of federal policy, manufacturer-led digital distribution, and telehealth integration has drastically lowered the cost of GLP-1 medications outside the traditional insurance system.

Shifting access

Up until recently, GLP-1 medications like semaglutide and tirzepatide remained largely out of reach for patients without generous insurance coverage, costing upwards of $1000 to $1349 USD per month, reports Zhan.

However, in early 2026, prices dropped below $350 USD due to three distinct forces: federal Most-Favored-Nation pricing deals, the launch of direct-to-consumer platforms by pharmaceutical manufacturers like Novo Nordisk and Eli Lilly, and the integration of GLP-1 prescribing into telehealth startups and mainstream retail. These forces culminated in the launch of TrumpRx.gov, a federal platform connecting cash-paying patients to reduced medication prices.

The continuity problem

While lower prices have expanded access, sustaining treatment remains a significant challenge. Because this new cash-pay model operates entirely outside the insurance system, purchases do not count toward deductibles or out-of-pocket maximums, leaving patients who need indefinite treatment without financial protection.

Furthermore, the foundation of some direct-to-consumer platforms remains uncertain, as leading telehealth providers face FDA shipping restrictions and patent infringement lawsuits over lower-cost compounded GLP-1 products.

Broader implications

Though continuity remains an issue, this access model has the potential to expand beyond GLP-1s to other chronic condition treatments, including $25 monthly insulin and heavily discounted COPD inhalers—potentially reshaping how Americans access treatment.

"GLP-1s are, in effect, a test case for whether a viable access pathway for chronic disease medications can be sustained outside the insurance system," Zhan writes. Ultimately, the long-term success of this model will depend on whether this digital infrastructure can support continuous care.

Publication details

Zhan XJ. Affordable GLP-1? When Digital Platforms Meet Policy Reform, Journal of Medical Internet Research (2026). DOI: 10.2196/102069

Journal information: Journal of Medical Internet Research

Key medical concepts

Glucagon-Like Peptide-1 Receptor AgonistsSemaglutideTirzepatideInsulin

Clinical categories

EndocrinologyWeight management Provided by JMIR Publications Who's behind this story?

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: How digital platforms and policy shifts reshape GLP-1 affordability (2026, June 1) retrieved 1 June 2026 from https://medicalxpress.com/news/2026-06-digital-platforms-policy-shifts-reshape.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.